Covid 19 Research using Clinical Trials (Home Page)
Report for D001049: Apnea NIH
(Synonyms: Apnea)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug638 | Polysomnography Wiki | 1.00 |
| drug132 | Blood sample Wiki | 0.58 |
Correlated MeSH Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D020181 | Sleep Apnea, Obstructive NIH | 1.00 |
| D012891 | Sleep Apnea, NIH | 1.00 |
| D011014 | Pneumonia NIH | 0.08 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Impact of Obstructive Sleep Apnea on Covid-19 Outcomes (OSACOVID-19 Study): A Prospective Observational Cohort Study
Covid-19 infection is an on-going pandemic with worse diagnosis in adults with comorbid conditions such as hypertension and cardiopulmonary diseases. Obstructive sleep apnea (OSA) is common in those comorbidities and may contribute to worse prognosis for the Covid-19 cases.
NCT04363333 COVID Obstructive Sleep Apnea Pneumonia Diagnostic Test: Polysomnography MeSH:Apnea Sleep Apnea Syndromes Pneumonia Sleep Apnea, Obstructive
HPO:Apnea Obstructive sleep apnea Pneumonia Sleep apnea
Primary Outcomes
Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 28 days
Secondary Outcomes
Description: Time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality
Measure: Clinical status Time: 7, 14, 21, 28 days
Other Outcomes
Description: Re-analysis of the correlation of obstructive sleep apnea (objectively verified) severity in terms of apnea-hypopnea index and oxygenation levels with the primary and secondary outcomes as described above (the rate of clinical improvement defined as a decline of 2 categories from admission on a 7-category ordinal scale; time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality as well as with the lung function, CO-diffusion capacity, cardiac function, CT thorax pathologies, biomarkers (cytokines, polymorphisms) and IgG-antibodies after 4 months.
Measure: Long-term outcomes Time: 4 months after the initial hospital admission
HPO Nodes
HP:0002104: Apnea
Genes 319
ACY1 KCNQ2 SNORD116-1 ND5 PLAA CPLANE1 PRPH NDUFA4 PDE6D TRNW ECHS1 ND6 COX15 DNA2 KIF7 CHRNE TRNV ND4 NDUFS8 ARL3 SLC2A1 NDUFAF3 TCTN1 MCCC1 NDUFS3 GPR101 MKRN3 GLRA1 CEP290 GBA CSPP1 SOD1 SURF1 GSN COLQ FBP1 PCK1 ASCL1 ATN1 MYO9A NDUFS4 AGRN TMEM216 TRNQ ASCL1 GABBR2 SLC19A3 GDNF SLC25A20 NADK2 SLC18A3 HMGCL SCN4A RPGRIP1L IDS SLC39A8 NGLY1 LTBP3 CC2D2A PRPS1 NDUFS7 MECP2 HTRA2 TECPR2 FGFR3 INPP5E FGFR2 TSEN54 BRAF PWRN1 FGFR3 ND2 DKK1 MKS1 WFS1 INPP5E PLPBP EDN3 RPGRIP1L SURF1 PCCB AMER1 TRIP13 CCDC47 CEP57 PHOX2B CLCN7 PTF1A CTNNB1 BTD TRNF PLCB4 BTD NDUFS2 EP300 OFD1 BUB1B OPA1 PSAP FLCN TMEM67 GABRG2 SYT1 NDUFS2 COQ2 KAT6B BUB3 NDUFS1 TWIST1 HYLS1 AHDC1 CEP104 TMEM216 RET RUNX2 ZNF423 TCTN3 SNORD115-1 RAI1 CSPP1 PIBF1 TSPYL1 PDHA1 MKS1 TSPYL1 MYO9A FAM149B1 TMEM237 NDUFAF2 BRAT1 ND6 SCN2A NDUFS1 IDUA AIP SKI GNE ACADSB CEP41 ND5 ECHS1 GPHN LAMB2 SLC5A7 CTSD KIF5A ALPL RPS6KA3 NONO HERC2 LIFR BRAT1 NDUFA11 TMEM138 CC2D2A SNRPN LIFR TMEM67 TNFSF11 SRPX2 KIAA0586 ATP5F1A NDUFA2 RPGRIP1L FGFR2 KIAA0586 FGFR3 TRNH SNAP25 RET RARS2 ND3 IPW MAGEL2 SCN5A SLC6A5 BUB1 INPP5E NPAP1 TCTN2 LARP7 FGFR3 B9D1 NDUFV1 SLC52A3 TRNL1 DNA2 PRNP ND4 NGLY1 CEP120 PEX5 SDHA INPP5E P4HTM ARCN1 SLC18A3 NDUFAF6 ABCA3 NDUFA2 ARMC9 COQ2 GRIN2A TMEM237 DCTN1 SFTPB TACO1 HSPD1 KIAA0753 NDUFAF2 TRNS2 CEP290 SCN4A SNX10 CEP41 PIBF1 NDUFA10 NDUFV2 CHAT CISD2 NDUFAF5 FARS2 TRNS1 KIAA0556 NDUFB8 CHAT RNF125 TMEM107 TCF4 NDUFV1 TRPV4 TOE1 PHOX2B IDUA GNAI3 TRNL1 EDN1 VAMP1 TMEM231 CPT2 DPAGT1 ND1 LIPT1 HSPG2 NDN COX1 MECP2 FBN1 KIAA0586 MAGEL2 CEP120 TMEM216 MKRN3-AS1 SLC25A1 SLC5A7 RERE PCGF2 NDUFA12 AHI1 NDUFA13 ND1 GLUL TMEM237 SH3BP2 D2HGDH SCO2 PWAR1 TCF4 AHI1 ARMC9 SLC52A2 GNAI3 NDUFA9 NEK1 TRNW COX3 RBM10 SLC6A9 LIAS GPR101 AHI1 PLCB4 TRNK COL13A1 COX2 SOX9 MTFMT PDHA1 TECPR2 SYT2 NFIX HRAS PLAA POGZ NPHP1 DST PET100 TCIRG1 PCCA NEB GBA CEP57 CPLANE1 FOXRED1 TBR1 CRYAB ATP6 CREBBP SKI PEX13 ARL13B COL3A1 GNE ZC4H2 CSPP1 FBP1 BMP2 NDUFS8 NEFH SNP 1
rs9526240
Primary Outcomes
Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 28 daysSecondary Outcomes
Description: Time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality
Measure: Clinical status Time: 7, 14, 21, 28 daysOther Outcomes
Description: Re-analysis of the correlation of obstructive sleep apnea (objectively verified) severity in terms of apnea-hypopnea index and oxygenation levels with the primary and secondary outcomes as described above (the rate of clinical improvement defined as a decline of 2 categories from admission on a 7-category ordinal scale; time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality as well as with the lung function, CO-diffusion capacity, cardiac function, CT thorax pathologies, biomarkers (cytokines, polymorphisms) and IgG-antibodies after 4 months.
Measure: Long-term outcomes Time: 4 months after the initial hospital admission